North America’s Stem Cell Market 2019-2024 – Growing Demand for Regenerative Treatment Options – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North
America Stem Cell Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.

The North American stem cell market is expected to witness a CAGR of
9.5% during the forecast period.

Certain factors that are driving the growth of the market include the
increase in the approval for clinical trials in stem cell research,
growing demand for regenerative treatment options, and rising R&D
initiatives to develop therapeutic options for chronic diseases.

The market for stem cell is growing, along with the increasing clinical
trials around the region. North America, especially the United States,
dominated the overall market in terms of the number of trials undergoing
in the stem cell therapies. The United States dominates the market in
both product type and banking services, holding around 77.4% of the
total North American market.

Stem cells play a major role in regenerative medicine, especially in the
field of dermatology. However, oncology is expected to register the
highest growth rate, due to a large number of pipeline products in the
treatment for cancers. With the increase in the number of regenerative
medicine centers, the cell market is also expected to grow in the future.

Stem cells banking is gaining prominence with the support of government
initiatives. The number of stem cell banks is increasing in the region,
which is aiding the growth of the market. Moreover, increasing awareness
about stem cell storage among people has also positively affected the
market.

Oncology Disorders is Expected to Show Lucrative Growth in
the Therapeutic Application Type

Cancer has had a major impact on US society as well as the North
American region. As per the estimates of the National Cancer Institute,
in 2018, 1,735,350 new cases of cancer were anticipated to be diagnosed
in the United States, and 609,640 deaths were expected from the disease.
The increasing medical burden can be attributed to population growth.
Bone marrow transplant or stem cell transplant is a treatment for some
types of cancer, such as leukemia, multiple myeloma, multiple myeloma,
neuroblastoma, or certain types of lymphoma.

Embryonic stem cells (ESC) are the major source of stem cells for
therapeutic purposes, due to higher totipotency and indefinite lifespan
compared to adult stem cells with lower totipotency and restricted
lifespan. However, the use of ESCs for research and therapeutic purposes
is restricted and prohibited in many countries throughout the world, due
to ethical constraints. Scientists from the University of California,
Irvine, created a stem cell-based approach to kill cancerous tissue,
preventing some of the toxic side effects of chemotherapy by treating
the disease in a more localized way.

Although the market shows a positive growth due to the growing focus of
stem cell-based research that can further strengthen the clinical
application, the expensive nature of stem cell therapy may still hamper
its growth.

Competitive Landscape

The North American stem cell market, which is highly competitive,
consists of a number of major players. Companies, such as Becton,
Dickinson and Company, Biotime Inc., Brainstorm Cell Therapeutics, Juno
Therapeutics, International Stem Cell Corp., Miltenyi Biotec, Osiris
Therapeutics Inc., Sigma Aldrich (A Subsidiary of Merck KGaA), Stem Cell
Technologies, and Thermo Fisher Scientific, among others, hold a
substantial market share in the market studied.

Key Topics Covered

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Introduction to Market Drivers and Restraints

4.3 Market Drivers

4.3.1 Increase in the Approval for Clinical Trials in Stem Cell Research

4.3.2 Growing Demand for Regenerative Treatment Option

4.3.3 Rising R&D Initiatives to Develop Therapeutic Options for Chronic
Diseases

4.4 Market Restraints

4.4.1 Expensive Procedures

4.4.2 Regulatory Complications

4.4.3 Ethical and Moral Framework

4.5 Porter’s Five Forces Analysis

5 MARKET COMPETITION

5.1 By Product Type

5.1.1 Adult Stem Cell

5.1.2 Human Embryonic Cell

5.1.3 Pluripotent Stem Cell

5.1.4 Other Product Types

5.2 By Therapeutic Application

5.2.1 Neurological Disorders

5.2.2 Orthopedic Treatments

5.2.3 Oncology Disorders

5.2.4 Diabetes

5.2.5 Injuries and Wounds

5.2.6 Cardiovascular Disorders

5.2.7 Other Therapeutic Applications

5.3 By Treatment Type

5.3.1 Allogeneic Stem Cell Therapy

5.3.2 Auto logic Stem Cell Therapy

5.3.3 Syngeneic Stem Cell Therapy

5.4 By Banking Service and Technology

5.4.1 Stem Cell Acquisition and Testing

5.4.2 Cell Production

5.4.3 Expansion

5.4.4 Sub-culture

5.4.5 Cryopreservation

5.5 By Type of Banking

5.5.1 Public

5.5.2 Private

5.6 Geography

5.6.1 United States

5.6.2 Canada

5.6.3 Mexico

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Becton, Dickinson and Company

6.1.2 Biotime Inc.

6.1.3 Brainstorm Cell Therapeutics

6.1.4 International Stem Cell Corp.

6.1.5 Juno Therapeutics

6.1.6 Miltenyi Biotec

6.1.7 Osiris Therapeutics Inc.

6.1.8 Sigma Aldrich (A Subsidiary of Merck KGaA)

6.1.9 Stem Cell Technologies

6.1.10 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/ku75g7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Stem
Cells